Periodontitis, obesity and diabetes mellitus
Bruno S. Herrera and Filippo Graziani
In the last two decades, researchers have looked more deeply into the association of periodontitis and common major systemic chronic pathologies such as atherosclerosis1, diabetes2, obesity3, and preterm labour4 with adverse pregnancy outcomes5. The rationale of the periodontal-systemic link likely involves two important mechanisms: systemic inflammation and bacteraemia. One of the most important systemic diseases in this field is diabetes mellitus (DM). DM is a group of metabolic diseases characterised by hyperglycaemia due to decrease in insulin secretion, insulin response or both. The chronic hyperglycaemia of diabetes is associated with long-term damage, dysfunction, and failure of various organs, especially the eyes, kidneys, nerves, heart and blood vessels6. The vast majority of cases of diabetes fall into two broad aetiopathogenetic categories: type 1 (T1DM) and 2 (T2DM). T1DM is the absolute deficiency of insulin secretion due to autoimmune beta-cell destruction in the pancreas. T2DM develops when there is an abnormally increased resistance to the action of insulin and the body cannot produce enough insulin to overcome the resistance6,7.
Overweight and obesity involve abnormal or excessive fat accumulation that may impair health and are considered major risk factors for a number of chronic diseases, including diabetes, cardiovascular diseases and also periodontitis8. Childhood obesity results in the same conditions, with premature onset, or with greater likelihood of developing these diseases as adults. Thus, the economic and psychosocial costs of obesity alone, as well as when coupled with these comorbidities are striking9. According to the World Health Organization (WHO)8, in 2016, more than 1.9 billion adults were overweight and, of these, over 650 million were obese. Worldwide obesity has nearly tripled since 1975 and most of the world’s population live in countries where overweight and obesity kills more people than underweight. This epidemic is far from its resolution, since 41 million children under the age of 5 and over 340 million children and adolescents aged 5 to 19 were overweight or obese in 20168.
Body mass index (BMI, calculated as weight in kg/height in metres2) provides the most useful population-level measure of overweight and obesity. However, it should be considered a rough guide because it may not correspond to the same degree of fatness in different individuals. For adults, the WHO defines overweight as a BMI greater than or equal to 25; and obesity a BMI greater than or equal to 308. Another way to assess this information is to use Z-scores (also known as standard deviation scores). It is obtained by dividing the median weight of the reference person or population by the standard deviation height or age of the reference population. Z-scores are sex-independent, thus permitting the evaluation of children’s growth status by combining sex and age groups (Table 1-1). There are several factors that increase obesity risk, such as parental diet and/or obesity, a sedentary lifestyle, famine exposure, smoking, and alcohol binge drinking and regular high consumption, especially in women9,13. In addition, to date, over 60 relatively common genetic markers have been implicated in elevated susceptibility to obesity9.
Table 1-1 Common classifications of body weight in adults and children9
|Age group||Age||Indicator||Normal weight||Overweight||Obese|
|Adults||≥ 20 y||BMI (kg/m2)||18.5–24.99||25.00 to 29.99||≥ 30.00|
|Class 1: ≤ 34.99|
|Class 2: ≤ 39.99|
|Class 3: ≥ 40.00|
|Children||WHO Multicentre Growth Reference Study Group10||0–60 mo||BMI Z or WH Z||> −2 to ≤ 2 SD. At risk of overweight: > 1 to ≤ 2 SD||> 2 to ≤ 3 SD||> 3 SD|
|de Onis et al11 (WHO)||5–19 y||BMI Z||> −2 to ≤ 1 SD||1 to ≤ 2 SD||> 2 SD|
|Kuczmarski et al12 (CDC)||2–19 y||BMI percentile||≥ 5th to < 85th||≥ 85th to < 95th||≥ 95th|
MI = body mass index; CDC = Centers for Disease Control and Prevention; SD = standard deviation of the optimum weight-for-height; WH = weight-for-height; WHO = World Health Organization; Z = Z-score.
In the USA, a 2005 estimation indicated that obese men are thought to incur an additional US $1152 annually per person in medical spending, while obese women incur over double that. The authors estimate that around US $190 billion per year, approximately 21% of US health care expenditure, is due to treating obesity and obesity-related conditions14. In Europe, a 2008 review of 13 studies in 10 western European countries estimated the obesity-related health care burden had a relatively conservative upper limit of €10.4 billion annually15,16.
1.1.2 Diabetes mellitus
Diabetes was first described in the Ebers Papyrus in 1500 BC, when it was called ‘too great emptying of the urine’. At the time, physicians from India observed that the urine from people with diabetes attracted ants and flies, calling it ‘honey urine’. In 1776, the British physiologist Matthew Dobson first described that the sweet-tasting substance in the urine was sugar. However, it was only in the nineteenth century that glycosuria became an accepted diagnostic criterion for diabetes, after Michel Eugène Chevreul observed in 1815 that the sugar found in urine was glucose and after Hermann Von Fehling developed a quantitative test for glucose in urine in 184817. Between 1893 and 1909, several researchers, including Paul Langerhans, observed that insulin deficiency was the factor responsible for the development of diabetes. Prior to its isolation and clinical use in 1922 by Frederick Banting and Charles Best, the only known treatment for diabetes was starvation diets, with not uncommonly death from starvation in some patients with diabetes T2DM17. Regarding oral hypoglycaemic agents, in 1918, C. K. Watanabe observed that guanidine caused hypoglycaemia17. Ten years later, biguanidine, a guanidine-modified molecule, was introduced for treatment of diabetes in Europe17. In 1949, Becton, Dickinson and Company began the production of a standardised insulin syringe designed and approved by the American Diabetes Association (ADA). The standardised syringe reduced dosing errors and the associated episodes of hyperglycaemia and hypoglycaemia.
Diabetes impacts more than 415 million people worldwide and two thirds of people with diabetes die of heart disease and stroke18. In addition, the risk for cardiovascular disease mortality is two to four times higher in people with diabetes than in people who do not have diabetes7. Diabetes is a disease that rarely occurs alone. When it is combined with abdominal obesity, high cholesterol and/or high blood pressure, it becomes a cluster of the highest risk factors of heart attack. The combination of these diseases is termed metabolic syndrome (MS), also known as insulin-resistance syndrome or cardiometabolic syndrome. According to the most recent guidelines issued in 2009 by the International Diabetes Federation (IDF), American Heart Association (AHA) and the National Heart, Lung, and Blood Institute (NHLBI), MS is defined as the combination of at least three of the following conditions: increased plasma glucose (≥ 100 mg/dl), hypertension (≥ 130/85 mmHg or systemic arterial hypertension treatment), hypertriglyceridaemia (≥ 150 mg/dl), low high-density level cholesterol (HDL, < 40 mg/dl) and/or elevated abdominal circumference (≥ 94 cm + ethnicity-specific values)19.
MS is a major public health challenge worldwide since it is associated with a five-fold elevated risk of T2DM and a two- to three-fold risk of cardiovascular disease20. MS predicts diabetes independently of other factors. However, obesity worsens the diabetes risk associated with MS or impaired glucose tolerance, due to its relation to insulin resistance and due to being the central element of MS21. Data from the third National Health and Nutrition Examination Survey (NHANES III) in adults aged 50 years or older indicated that the prevalence of coronary heart disease was greatest in individuals with MS and DM combined22.
Circulating blood glucose binds to, and therefore glycates, the red blood cell protein haemoglobin. This glycation occurs proportionally to the blood glucose concentration. By measuring the percentage of glycated haemoglobin (HbA1c) in the blood, the average blood glucose over the past 2 to 3 months and a person’s success in controlling their blood glucose can be estimated23.
According to the position statement published by the ADA in 201824, it is suggested that the HbA1c should be less than 7% for non-pregnant adults, which is an average glucose concentration of 154 mg/dl or 8.6 mmol/l (Table 1-2). However, it can be less stringent; for example, in patients with a history of severe hypoglycaemia, long-standing diabetes and limited life expectancy, < 8% is acceptable. The HbA1c test should be conducted at least two times per year in patients who are meeting the treatment goals and who have stable glycaemic control, and quarterly in patients whose therapy has changed or who are not meeting glycaemic goals24.
Table 1-2 The relationship between haemoglobin A1c (A1C) and estimated average glucose (eAG, calculated by the formula eAG = 28.7 × A1c − 46.7)
Diabetes and its complications are a major cause of morbidity and mortality worldwide and contribute substantially to health care costs. The major complications of DM are divided into: microvascular (retinopathy, nephropathy and neuropathy) and macrovascular complications (cardiovascular diseases and lower-extremity amputation). It has been proposed by Loe25 that periodontitis would be the sixth complication of diabetes. According to the Consensus Report of the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions26, there are no characteristic phenotypical features that are unique to periodontitis in patients with DM, so the level of glycaemic control in diabetes influences the grading of periodontitis and it should be included in a clinical diagnosis of periodontitis as a descriptor. In addition, most of the evidence for its adverse effects on periodontal tissues is from patients with T2DM. However, the level of hyperglycaemia over time, irrespective of the type of diabetes, is of importance when it comes to the magnitude of its effect on the course of periodontitis26. Therefore, the aim of this chapter is to discuss the evidence for the bidirectional association, epidemiology and mechanisms linking periodontitis, obesity and DM.
● Worldwide, more than 1.9 billion adults are overweight and, of these, over 650 million are obese.
● Overweight and obesity have genetic, behavioural, socio-economic and environmental origins.
● Paradoxically, coexisting with undernutrition, an escalating global epidemic of obesity – also known as ‘globesity’ – is taking over many parts of the world.
Annually, the cost of globesity is around US $190 billion per year in the USA and €10.4 billion in Europe.
1.2.1 Periodontitis and obesity
The association between obesity and periodontitis was first reported in 1977, when changes in the periodontium of obese rats was found27. The first human study reporting this relationship was conducted by Saito et al28. In this study, the periodontal status of 241 healthy Japanese subjects was assessed. The authors observed that the relative risk of periodontitis was 3.4 in subjects with BMIs of 25.0 to 29.9 kg/m2, and 8.6 in those with BMIs of ≥ 30 kg/m2, compared with subjects with BMIs of < 20 kg/m2 28. Since then, some systematic and non-systematic reviews have been published regarding this association. However, the level of evidence is low, as they include mainly cross-sectional studies, whilst prospective evidence is scarce29. In addition, there are several confounding factors related to obesity that should be clarified to elucidate the direction of this association. In a systematic review, Moura-Grec et al30 found an association between periodontitis and obesity in 17 studies, a trend in 8 studies, and no association in 6 studies. When they compared normal weight, overweight and obesity, they observed an odds ratio (OR) of 1.30 (95% confidence interval [CI] 1.25 to 1.35) of the risk to have periodontitis in an obese subject. Data from a systematic review by Keller et al29 including interventional and longitudinal studies showed that overweight31, obesity31,32, weight gain32 and increased waist ratio27,28 are risk factors directly associated with developing or worsening periodontitis.
Jimenez et al31 examined the association between measures of adiposity and self-reported periodontitis, using data from more than 36,000 healthy male participants of the Health Professionals Follow-Up Study, who were periodontally healthy at baseline and were followed for more than 20 years. They observed that overweight and obesity increase the risks of having periodontitis (hazard ratio [HR] 1.09, 95% CI 1.01 to 1.17, and HR 1.30, 95% CI 1.16 to 1.45, respectively). When the obesity data was broken down among dental and non-dental professionals, they only observed a significant association in the first group (HR 1.52, 95% CI 1.32 to 1.75 vs. HR 1.07, 95% CI 0.90 to 1.27). Regarding the waist ratio, subjects with more than 40.25 inches in waist circumference exhibited a 25% (95% CI 1.09 to 1.44) increased risk of periodontal disease compared with men with less than 40.25 inches. All data were adjusted by age, number of teeth at baseline, physical activity or fruit and vegetable intake. It is important to highlight that periodontitis was self-reported in this study, thus the lack of an expert diagnosis is likely to introduce some errors and biases in the study outcomes.
Gorman et al32 found that a 1% increment in waist-to-height ratio was associated with a 3% increase in the HR of having periodontitis progression over 27 years, and an augmentation of 1 cm in waist circumference was associated with a 1% to 2% increase in the hazard of periodontitis in 1038 white males. Obese subjects had an HR of 1.52 (95% CI 1.05 to 2.21) for having clinical attachment loss greater than 5 mm and an HR of 1.60 (95% CI 1.07 to 2.38) of having alveolar bone loss greater than 40% of more than two teeth when compared to normal weight counterparts. Furthermore, treatment outcomes may be diminished by obesity: Martinez-Herrera et al33 reported, in their systematic review, that obesity had an impact on the outcome of scaling and root planing in patients with periodontitis in three of the 28 studies included. On the other hand, six studies did not show this impact. Conclusions are difficult to draw because of the high methodological heterogeneity in terms of evaluation of the periodontitis outcome measures used, risk factors analysed, and age and gender of the participants in the different studies. In a cross-sectional study published by the same group, the authors observed that periodontitis was more prevalent in obese subjects (80.9% vs. lean 41.2%), with a six-fold increased risk of having periodontitis. In addition, obese subjects displayed higher diastolic blood pressure, increased circulating tumour necrosis factor alpha (TNF-α) and high-sensitivity C-reactive protein (hsCRP), as well as lower high-density lipoprotein (HDL) than lean subjects. Interestingly, obese subjects with insulin resistance had higher systolic blood pressure, higher glucose, insulin, HbA1c and triglyceride levels, more insulin resistance (HOMA-IR [homeostatic model assessment of insulin resistance]), and a higher number of teeth with probing depths greater than 4 mm than those obese subjects without insulin resistance34.
D’Aiuto et al35 analysed data from almost 14,000 men and women from the third NHANES in the United States and observed that subjects older than 45 years with severe periodontitis were 2.31 times more likely to have metabolic syndrome, defined by concurrence of hypertension, atherogenic lipid profiles, obesity and insulin resistance; compared to unaffected individuals after adjusting for confounders. Furthermore, diagnosis of metabolic syndrome increased by 1.12 times per 10% increase in gingival bleeding and 1.13 times per 10% increase in the proportion of periodontal pockets. Morita et al36 followed up more than 3000 Japanese workers for 5 years and assessed the incidence of periodontitis. They observed a significant association between BMI and the development of periodontal pockets of greater than 4 mm, and the hazard ratios for women were higher than they were for men. However, this study used partial-mouth recording and the Community Periodontal Index to assess periodontal status, which would underestimate the true periodontal status. Merchant et al37 observed in 39,461 males that individuals who maintained a normal weight, pursued regular exercise, and consumed a diet in conformity with the Dietary Guidelines for Americans and the Food Guide Pyramid recommendations, were 40% less likely to have periodontitis.
In addition, periodontal pathogen populations seem to be altered in obese subjects. For example, Haffajee and Socransky38 observed an overgrowth of Tannerella forsythia in the biofilms of periodontally healthy obese individuals that might put them at risk for initiation of periodontitis. They also observed that the ORs of overweight and obese subjects exhibiting periodontitis were 3.1 (95% CI 1.9 to 4.8) and 5.3 (95% CI 2.8 to 9.5), respectively, when compared with subjects with normal BMI. Logistic regression analysis indicated an OR of 2.3 (95% CI 1.2 to 4.5) for an obese subject to exhibit periodontitis after adjusting for age, gender and smoking status. In a recent study, Maciel et al39 observed that obese male subjects with periodontitis harboured higher levels and/or higher proportions of periodontal pathogens, such as Aggregatibacter actinomycetemcomitans, Eubacterium nodatum, Fusobacterium nucleatum subspecies vincentii, Parvimonas micra, Prevotella intermedia, T. forsythia, Prevotella melaninogenica and Treponema socranskii when compared to normal weight subjects with periodontitis. Furthermore, the healthy sites of the obese subjects also exhibited higher proportions of some of the pathogens than the normal weight counterparts39.
In terms of treatment outcome, Suvan et al40 investigated the predictive role of overweight/obesity on clinical response following non-surgical periodontal therapy in 260 adults. On re-evaluation, i.e., after 8 weeks, they observed that obesity was an independent predictor of poorer periodontal treatment outcomes. These patients had, on average, 3.2% (95% CI 0.7% to 5.6%) more sites with probing depths greater than 4 mm when compared with normal weight subjects after adjustment for the baseline. For every BMI increase of 10 kg/m2, the mean percentage of sites with probing depths greater than 4 mm increased by 2.5% (95% CI 1.10% to 3.80%). No differences were found in bleeding on probing. It is worth pointing out that the magnitude of this association was similar to that of smoking, which was also linked to a worse clinical periodontal outcome40. However, Palomo41 stated that this study had limitations inherent in the study design. The confounders for periodontitis, such as smoking and diabetes, were not part of the exclusion criteria. Instead, statistical analysis was undertaken to account for them, increasing the risk for false-positive associations. Thus, a poor outcome after periodontal therapy in the obese patients of this study may in fact not be fully attributed to the BMI alone41.
It is difficult and complex to unravel the relative contributions of obesity and metabolic status, including hyperglycaemia, to periodontitis. Positive association between obesity and periodontitis has been consistently shown in recent meta-analyses. However, few of them have a prospective or a longitudinal design, and these relationships appear to be modest26. Taken together, there is significant evidence of an association between overweight/obesity and the prevalence, extent and severity of periodontitis, as well as periodontal treatment outcomes in children, adolescents and adults. However, the magnitude and mechanisms of this association require further clarification. The available evidence comes mainly from cross-sectional, experimental and longitudinal studies, respectively33,42. The difficulty to reach a final conclusion is related to the difficulty to evaluate the mechanisms underlying the association between them, because most of the studies involved a cross-sectional design. In addition, there is heterogeneity in the definition of obesity in most of the studies, which evaluate the degree of obesity by calculating BMI, however some of them also include wait-circumference, waist-hip ratio and, in some cases, percentage body fat. In order to confirm the causal relationship and the pathophysiological mechanism involved in the association between obesity and periodontitis, further prospective studies are needed33,42.
● A potential association between obesity and periodontitis was first reported in 1977.
● There are several confounding and risk factors related to obesity that should be adjusted for in future studies and biologically clarified to elucidate the association between obesity and periodontitis.
● Data from NHANES show that subjects older were 2.31 times more likely to have metabolic syndrome.
● 1% increment in waist-to-height ratio was associated with a 3% increase in the hazard of having periodontitis progression in a 2012 study.
● The overall level of evidence is low; therefore, an association cannot yet be confirmed.
1.2.2 Periodontitis and DM
Diabetes is one of the largest global health emergencies of the 21st century. In 2015, the International Diabetes Federation estimated that 415 million people worldwide have diabetes43. Despite better awareness and new developments in the treatment of diabetes and prevention, an unrelenting increase has been observed in the number of people with the disease. By 2040, an increase to 642 million is expected, where a major concern is low- and middle-income countries and in those countries that have experienced rapid economic growth44. The number could be higher, since there are numerous people from many countries that have the disease undiagnosed (especially in Africa, where it is estimated that more than 65% of individuals with diabetes remain undiagnosed)45.
The percentage of adults with diabetes increased with age, reaching a high of 25.2% among those aged 65 years or older46. The age-adjusted prevalence of diagnosed and undiagnosed diabetes is higher among Asians, non-Hispanic blacks, and Hispanics, respectively46. According to the ADA, the estimated costs associated with diabetes in the United States in 2002 totalled US $132 billion, with direct medical costs of US $92 billion and indirect costs (disability, loss in work productivity and premature mortality) of US $40 billion47. T1DM, previously referred to insulin-dependent diabetes or juvenile-onset diabetes, results from a cell-mediated autoimmune destruction of the insulin-producing pancreatic beta cells. It accounts for only 5% to 10% of those with diabetes6 and its prevalence increases at a rate of approximately 3% per year globally43. It frequently occurs in childhood; however, 84% of people living with T1DM are adults. It affects both genders equally46 and decreases life expectancy by an estimated 13 years48.
For over 70 years, researchers have been trying to understand the relationship between diabetes and periodontal diseases. The first study describing this relationship was published by Williams and Mahan49, who found that patients with poorly controlled diabetes required less insulin after treatment of periodontal infection with extractions and antibiotics. Years later, Grossi and Genco50 postulated a ‘self-feeding two-way system of catabolic response resulting in more severe periodontitis and increased difficulty controlling blood sugar’.
18.104.22.168 Pathogenesis of DM
T1DM is a disorder that arises following the autoimmune destruction of insulin-producing pancreatic beta cells, characterised histologically by insulitis (i.e., islet cell inflammation) and associated beta-cell damage. The disease is most often diagnosed in children and adolescents presenting with a classic trio of symptoms (polydipsia, polyphagia, polyuria) alongside hyperglycaemia51. Many different theories have been postulated to explain its development, including molecular mimicry leading to the generation of an autoimmune response, alteration of self-antigens to a now antigenic self, defective major histocompatibility complex (MHC) expression on cells of the immune system, breakdown in central tolerance, deleterious trafficking of dendritic cells from beta cells to pancreatic lymph nodes, sensitivity of the beta cells to free radical or cytokine-induced damage local viral infection and defects in peripheral immune tolerance52 (Table 1-3).
T2DM, previously referred to as non-insulin-dependent diabetes, or adult-onset diabetes, develops when beta cells fail to secrete sufficient insulin to keep up with the demand, usually in the context of increased insulin resistance53. The development of T2DM is caused by a combination of lifestyle and genetic factors. Some of these factors can be controlled, such as diet and obesity, and other factors cannot, such as increasing age, female gender and genetics. Most patients with this form of diabetes are obese and weight loss improves insulin sensitivity in liver and skeletal muscle tissues. Genome-wide association studies have identified more than 130 genetic variants associated with T2DM, glucose levels or insulin levels; however, these variants explain less than 15% of disease heritability54,55. The lifetime risk of developing T2DM is about 40% if one parent has T2DM and higher if the mother has the disease56. In comparison, the risk for T1DM is about 5% if a parent has T1DM and higher if the father has the disease57 (Table 1-3).
Table 1-3 T1DM vs. T2DM
|Autoimmune destruction of pancreatic beta cells||Over time, insulin receptors become less sensitive/insulin resistance – beta cells deteriorate over time|
|Children/teenagers are mostly affected||Adults, elderly and certain ethnic groups (African-American, Hispanic, Native American, Pacific Islander groups) are mostly affected|
|Lack of insulin||Obesity as risk factor|
|About 5% of all diabetes cases||About 95% of all diabetes cases|
|Involvement of kidneys, eyes and heart||Involvement of kidneys, eyes and heart|
|Diet and exercise cannot reverse the condition||Diet and exercise can reverse the condition|
|Extrinsic insulin requirement||Oral medication, insulin may be required|
T1DM: type-1 diabetes mellitus; T2DM: type-2 diabetes mellitus
22.214.171.124 Interventional studies on the impact of glycaemic control upon complications of diabetes
Large clinical trials demonstrated the need of the glycaemic control to avoid systemic-related complications of diabetes. The Diabetes Control and Complications Trial (DCCT) and its follow-up study, the Epidemiology of Diabetes Interventions and Complications (EDIC) were conducted in 29 medical centres in the United States and Canada. They included 1441 volunteers aged 13 to 39 years with T1DM, monitored from 1982 to 1993 (DCCT) and from 1994 to 2014 (EDIC), with a mean follow-up period of 6.5 years, and assessed the incidence and predictors of cardiovascular disease events such as heart attack or stroke, as well as diabetes complications related to the eye, kidney and nervous system. In the DCCT study, the patients were randomised to either receive intensive therapy (at least three insulin injections per day or continuous subcutaneous insulin infusion with external pumps) in order to maintain safe asymptomatic glucose control (with a target of pre-meal glucose level between 70 and 120 md/dl and post-meal glucose levels less than 180 mg/dl) or conventional control (one to two insulin injections per day). The average blood glucose was 155 mg/dl in the intense control group and 231 mg/dl in the conventional group. It was observed that HbA1c in the intensively controlled group was 2% lower than in the control group, with a 76% reduction in retinopathy, 34% in the development of early nephropathy and 69% in the development of neuropathy58. EDIC also observed that there was a reduction in cardiovascular events and death from cardiovascular disease when intense treatment in the previously conventionally controlled diabetes is provided59.
In another large randomised controlled trial, The United Kingdom Prospective Diabetes Study (UKPDS), 5102 patients with newly diagnosed T2DM in 23 centres within the UK were studied between 1977 and 1991. Patients were followed for an average of 10 years. Intensive therapy (insulin or oral agents) was compared to conventional therapy (diet with or without pharmacological therapy). This study provided strong evidence that intense glycaemic control in T2DM (median HbA1c of 7.0% vs. 7.9%) can decrease the morbidity and mortality of the disease by decreasing its chronic complications. As observed in T1DM clinical trials, such as DCCT and EDIC, lowering blood glucose levels decreases retinopathy, nephropathy and possibly neuropathy, showing that hyperglycaemia is the cause of, or at least the major contributor to these complications. In addition, the epidemiological analysis of the UKPDS data showed that for every percentage point decrease in HbA1c, there was a 35% reduction in the risk of microvascular complications, 25% in diabetes-related deaths, a 7% reduction in all-cause mortality, and 18% in myocardial infarction. Importantly, there is no glycaemic threshold for these complications above normal glucose levels60,61. Taken together, DCCT and UKPDS, along with other studies, demonstrate that glycaemic control is the key factor to control systemic complications related to DM.
126.96.36.199 Association between periodontitis and DM
The relationship between periodontitis and diabetes has been a subject of several longitudinal and interventional studies and it has been suggested that their relationship is bidirectional in both T1DM and T2DM and periodontal diseases62. For example, in diabetes, local inflammatory reactions within the periodontal tissues are modulated by the associated metabolic dysregulation (i.e. tissue responses to inflammatory stimuli are enhanced in poorly controlled diabetes)63, which is explained in further detail in Section 1.3 ‘Cellular and molecular mechanisms’.
Diabetes and periodontitis are chronic inflammatory diseases that have been considered to be biologically linked. Diabetes is known to be a primary risk factor for periodontitis, and periodontitis is considered as the sixth complication of DM25. Evidence linking periodontitis and diabetes began to emerge in the 1990s from several studies conducted in the Pima Indian population in the United States64. Cross-sectional studies showing the prevalence and longitudinal studies showing the incidence of diabetes, demonstrate that periodontitis is significantly more abundant in subjects who have T1DM65 or T2DM66 diabetes, with a higher risk of having the severe forms of periodontitis. The risk of periodontitis is approximately three to four times higher in people with T2DM than in non-diabetes subjects67. The direct relationship between the glucose level and the severity of periodontitis has been demonstrated, with the ORs in T2DM patients of periodontal destruction being 1.97 in well, 2.10 in moderately, and 2.42 in people with poorly controlled diabetes68. In addition, data from the NHANES show that individuals with diabetes are at greater risk for incident and prevalent periodontitis and have more severe periodontitis than individuals without diabetes, after controlling for age, education, smoking status and calculus69. These data were also supported by a recent meta-regression analysis of longitudinal studies, which included 13 studies. The authors reported that diabetic subjects present a 70% higher incidence or progression risk of periodontitis than non-diabetics (relative risk [RR] 1.86, 95% CI 1.3 to 2.8), despite of high heterogeneity between studies70. Similarly, a 2019 Taiwanese large-scale cohort study, including 39,384 patients with new-onset diabetes and 39,384 subjects without periodontitis, found that patients with diabetes had a higher risk for periodontitis compared with the patients without diabetes (adjusted hazard ratio 1.04, 95% CI 1.01 to 1.08). As a major shortcoming, however, periodontitis was poorly defined, using ICD-9-CM (International Classification of Diseases, Ninth Revision, Clinical Modification) codes only71. Conversely, a systematic review and meta-analysis of 12 intervention studies (follow-up period: 6 months) published in the same year, stated that there was no significant difference in pocket reduction or clinical attachment gain between periodontitis patients and those with both diabetes and periodontitis. Furthermore the level of HbA1c at baseline did not affect the difference in pocket reduction. However, this study pooled data from smokers and non-smokers, which is likely to have affected treatment outcomes and therefore the results of this meta-analysis. Furthermore, heterogeneity of the included studies with regard to periodontal diagnosing as well as the relatively short follow-up period may have impacted the results72.
● In 2015, it was estimated that 415 million people worldwide have diabetes.
● By 2040, an increase to 642 million is expected.
● The estimated costs associated with diabetes in the United States in 2002 were US $132 billion.
● Intense glycaemic control in both T1DM and T2DM can decrease the morbidity and mortality.
● For every percentage point decrease in HbA1c, there are:
– 35% reduction in the risk of microvascular complications,
– 25% reduction in diabetes-related deaths,
– 7% reduction in all-cause mortality,
– 18% reduction in combined fatal and nonfatal myocardial infarction.
On the other hand, there is evidence for periodontitis promoting the development of diabetes. Overall, six studies with a total sample of 77,716 participants from the United States, Japan and Taiwan demonstrated that patients with periodontitis exhibit a higher chance of developing pre-diabetes and diabetes2. One of these studies demonstrated that systemically healthy subjects with probing depths equal to or greater than 6 mm have a 3.45 times higher risk of developing diabetes than those without periodontitis73. Another study demonstrated that subjects with gingivitis have a 40% elevated risk, subjects with periodontitis a 50% elevated risk, and subjects who are partially edentulous a 70% elevated risk of developing T2DM. It is important to mention that this association was observed in non-smoking subjects with normal weight74. This association can also be seen for gestational DM75. Furthermore, a recent (2019) study was conducted in 139 periodontitis patients, which employed chair-side screening for HbA1c levels and considered BMI, waist circumference and periodontal parameters. It was found that almost 25% of the subjects had unknown hyperglycaemia and those with HbA1c ≥ 5.7% displayed higher proportions of sites with clinical attachment loss > 5 mm76.
One recently published longitudinal study followed 2047 subjects aged 20 to 81 years from the Study of Health in Pomerania cohort over a period of 11 years. Although the study was well conducted and excluded many potential biases, it reported no association between periodontal parameters and either diabetes incidence or long-term changes in HbA1c. One shortcoming of this study may be, however, that diabetes was assessed by different methods (self-reporting or antidiabetic medication intake or HbA1c levels or fasting blood glucose)77.
Moreover, the majority of the studies report an association between worse periodontal conditions and diabetes complications. For example, Shultis et al78 observed that moderate and severe periodontitis, as well as edentulousness, significantly predicted both macroalbuminuria (2.0, 2.1 and 2.6 times higher, respectively) and end-stage renal disease in a dose-dependent manner among Pima Indians with T2DM. In this population, as shown by another study, those with severe periodontitis had a 3.5 times higher risk for cardiorenal death; moreover, nephropathy and death from ischaemic heart disease were significantly predicted by periodontitis79. In a systematic review and meta-analysis of 27 epidemiological studies, Ziukaite et al80 observed that the prevalence of diabetes was 13.1% among subjects with periodontitis and 9.6% among subjects without periodontitis. Interestingly, for subjects with periodontitis, the prevalence of diabetes was 6.2% when diabetes was self-reported, compared to 17.3% when diabetes was clinically assessed. According to this study, the highest prevalence of diabetes among subjects with periodontitis was observed in studies originating from Asian countries (17.2%) and the lowest in studies describing populations from Europe (4.3%). The overall OR for patients with diabetes among those with periodontitis was 2.27, compared to those without periodontitis. However, there was a substantial variability in the definitions of periodontitis, a combination of self-reported and clinically assessed diabetes, and a lack of assessment of confounding for diabetes in the included studies, introducing estimation bias80.
Nevertheless, according to Graziani et al2, periodontitis has an impact on diabetes control, including its incidence and complications. Poor glycaemic control and a higher risk of developing diabetes are observed in systemically healthy individuals with periodontitis. Diabetic individuals with periodontitis demonstrate a worsening of glycaemic control and significantly higher prevalence of diabetes-related complications. For example, patients with T2DM and comorbid periodontitis have significantly more cardiorenal complications (OR 3.5, 95% CI 1.2 to 10.0)81, neuropathic foot ulcerations (OR 6.6, 95% CI 2.3 to 18.8)82, cardiovascular complications (OR 2.6, 95% CI 1.6 to 4.2)83 and overall mortality (RR 1.51, 95% CI 1.11 to 2.04 for each 20% increment in mean whole-mouth alveolar bone loss)84. However, the studies suffered from intrinsic limitations that render the overall applicability of the results weak. For example, some of the evidence was indirectly drawn from manuscripts that did not have the primary intention of assessing the effect of periodontitis on glycaemic control. In addition, there is heterogeneity in terms of adjustment of confounders as well as of the definitions of periodontitis. Furthermore, the possibilities of selective data reporting and publication bias cannot be excluded2.
Taken together, there is strong and significant evidence that DM has an impact on the prevalence and severity of periodontitis. This evidence has evolved from surveys, case-control studies, narrative reviews and systematic reviews, but mainly from epidemiological studies. The association appears to be similar in T1DM and T2DM; however, the available evidence is focused particularly on T2DM. There is little evidence that the clinical features of periodontitis in patients with DM differ from those without DM. Regarding the impact of periodontitis on DM, there is accumulating evidence that periodontitis contributes to the onset and persistence of hyperglycaemia, poorer glycaemic control in individuals with DM, and an increase in DM incidence85,86.
Consequently, if periodontitis has a role in diabetes, it would be logical to infer that periodontal therapy impacts circulating levels of inflammatory cytokines, adiponectin, insulin resistance and glycaemic control. Efforts have been made to understand the impact of periodontal therapy in diabetes control. It has been shown that periodontal treatment can improve glycaemic control, lipid profile and insulin resistance, reduce serum inflammatory cytokine levels and increase serum adiponectin levels in T2DM patients87. Sun et al87 studied 190 moderately to poorly controlled T2DM patients (HbA1c between 7.5% and 9.5%) with periodontitis. They observed that after 3 months of periodontal therapy, the serum levels of C-reactive protein, TNF-α, interleukin (IL)-6, fasting plasma glucose, HbA1c, fasting insulin and the HOMA-IR index decreased, the latter being a method for assessing insulin resistance from fasting blood glucose and insulin concentrations. Adiponectin was significantly increased in the treated group compared to the non-treated group87.
The positive impact of a non-surgical periodontal therapy on HbA1c was also observed in a recent study by D’Aiuto et al88. In this 12-month randomised clinical trial, 264 subjects were allocated to receive intensive periodontal treatment (IPT; whole mouth subgingival scaling, surgical periodontal therapy and supportive periodontal therapy every 3 months until completion of the study) or control periodontal treatment (CPT; supragingival scaling and polishing at the same time-points as in the IPT group). They observed that HbA1c was 0.6% (95% CI 0.3% to 0.9%) lower in the IPT group than in the CPT group after 12 months, with adjustment for baseline HbA1c, age, sex, ethnicity, smoking status, duration of diabetes and BMI88. The question that still remains is whether the observed benefits are sustained beyond 12 months.
The impact of periodontal treatment is largely witnessed by the systematic reviews on this topic. Engebretson and Kocher89 demonstrated in a meta-analysis that periodontal therapy significantly reduced HbA1c 3 to 4 months post-treatment, ranging from 0.27% to 1.03% (95% CI −0.54 to −0.19). In the latest update, Madianos and Koromantzos90 confirmed that non-surgical periodontal therapy reduced HbA1c in patients with diabetes. They observed that there was a reduction 3 to 4 months post-treatment, ranging from −0.27% (95% CI −0.46 to −0.07) to −1.03% (95% CI 0.36 to −1.70) and at 6 months post-treatment, the HbA1c reduction ranged from −0.02 (95% CI −0.20 to −0.16) to −1.18% (95% CI −0.72 to −1.64). The data derived from the meta-analysis clearly indicate the positive effect of periodontal decontamination on glycaemic control. It is important to highlight that this effect cannot be underestimated since, as shown before, for every percentage point decrease in HbA1c, there is a 35% reduction in the risk of microvascular complications, 25% reduction in diabetes-related deaths, a 7% reduction in all-cause mortality, and an 18% reduction in combined fatal and nonfatal myocardial infarction. This further reinforces the hypothesis of a link between periodontitis and diabetes90.
Conversely, in a multicentre, randomised clinical trial, Engebretson et al91 observed that non-surgical periodontal therapy did not improve glycaemic control in patients with T2DM. However, several authors indicate that the periodontal therapy provided in this study failed to clinically manage the periodontal infection, since the subjects still had high residual plaque levels (72%) and bleeding scores (42%) after the therapy. In addition, the mean HbA1c value at baseline was close to the therapeutic target, thus, a substantial improvement of the HbA1c by periodontal intervention could not be expected. Lastly, the subjects from the treatment group were obese (mean BMI 34.7), which would probably have masked any anti-inflammatory effect of successful periodontal treatment92.
The controversy regarding the effect of periodontal treatment on glycaemic control may be related to the heterogeneity of the trial designs. These are, for example, non-surgical vs. surgical periodontal therapy provided, the periodontal treatment outcomes assessed, the periodontitis definition used (severity vs. extent vs. both), the selection criteria for the type of DM (T1DM vs. T2DM vs. both), the variability in the range of levels of glycated haemoglobin, and the follow-up periods, where periods of 3 months to assess HbA1c changes may be considered too short23,86. Table 1-4 lists the most important interventional studies. It presents the effect of periodontal treatment on glycaemic control of T1DM and T2DM. Table 1-5 gives an overview of clinical studies investigating the association between periodontitis and T1DM.
Table 1-4 Interventional studies assessing the effect of periodontal treatment on metabolic control of T1DM and T2DM: treatment group
|Study, country||Groups||Periodontal inclusion criteria||Diabetes inclusion criteria||Therapy||Confounders controlled||Results||Effect|
|Masi et al93, UK||51 patients with T2DM and PD;
27 IPT; 24 CPT; Mean age: IPT, 56 ± 9 y, and CPT, 58 ± 11 y.
|≥ 15 teeth, ≥ 20 sites with PD ≥ 5 mm and radiographic bone loss.||T2DM according to the WHO criteria and confirmed in specialist.||IPT group received whole mouth SRP at the baseline and 2 mo later. Additional periodontal surgery was performed if there were deeper residual periodontal pockets. CPT patients received supra-gingival scaling and polishing at the baseline and 2 mo later.||Age, gender, race, smoking, BP, cholesterol, cytokines, ROS.||Patients in the IPT group had lower levels of HbA1c 6 mo after therapy compared to CPT patients (average between-group difference of 0.65%, 95% CI 0.22–1.14, P = 0.003).||Yes|
|D’Aiuto et al88, UK||264 patients with T2DM and PD; 133 IPT and 131 CPT; Mean age: IPT, 58.2 ± 9.7 y, and CPT, 55.5 ± 10 y.||≥ 20 periodontal pockets with PD > 4 mm, marginal alveolar bone loss of > 30%, and at least 15 teeth, with active signs of gingival inflammation rather than history of breakdown of periodontal soft and hard tissues.||T2DM (using WHO diagnostic criteria) for 6 mo or longer.||IPT: whole mouth SRP, surgical periodontal therapy, and supportive periodontal therapy every 3 mo until completion of the study. Control: supragingival scaling and polishing at the same time-points as in the IPT group.||Age, gender, ethnicity, smoking, duration of diabetes, BMI.||After 12 mo, HbA1c was 0.6% (95% CI 0.3–0.9; P < 0.0001) lower in the IPT group than in the control group.||Yes|
|Mauri-Obradors et al94, Spain||90 patients with T2DM and PD; 48 treatment group and 42 treatment control;
Mean age: treatment group, 61 ± 11 y, and control, 62 ± 11 y.
|Periodontitis (Armitage108) at least nine teeth present and > 30% of the probed gingiva with a depth and clinical attachment level ≥ 4 mm.||T2DM diagnosed at least 1.5 years prior the study.||Treatment group: OHI, supragingival scaling and polishing, whole mouth SRP and supportive periodontal therapy when needed until completion of the study. Control: OHI, supragingival scaling and polishing.||Groups matched for: age, sex, medications, duration of diabetes, tooth brushing frequency, interproximal brush use, weight.||After 6 mo, improvement of HbA1c in the treatment group (P = 0.019)||Yes|
|Engebretson et al91, USA||514 patients with T2DM and PD;
257 treatment group and 257 treatment control;
Mean age: treatment group, 56.7 ± 10.5 y, and control, 57.9 ± 9.6 y.
|≥ 16 natural teeth, CAL and PD > 5 mm in 2 or more quadrants.||T2DM for more than 3 mo; HbA1c 7.0% > 9.0%.||Control: OHI; Treatment group: SRP and chlorhexidine gluconate (twice daily for 2 weeks).||Age, gender, smoking, systemic disease.||After 3 and 6 mo, no statistically significant difference in the HbA1c between the two groups. Control: −0.11 to −0.09; Treatment group: −0.14 to −0.11; P = 0.55; 3 and 6 mo respectively.||No|
|Katagiri et al95, Japan||41 patients with T2DM and PD; no controls;
Mean age: 63.3 ± 9.9 y.
|≥ 10 remaining teeth, at least two sites with a PD ≥ 4 mm.||HbA1c 6.2% > 10.4%.||All patients had SRP plus 10 mg minocycline 4 times every other week, followed by additional supportive periodontal treatments after 2 and 6 mo.||Age, gender, BMI.||After 2 and 6 mo, no statistically significant difference in the HbA1c. Baseline: 7.3 ± 0.8, 2 mo: 7.2 ± 0.7, 6 mo: 7.1 ± 0.6.||No|
|Moeintaghavi et al96, Iran||40 patients with T2DM and PD; 22 treatment group, 18 treatment controls;
Mean age: 50.29 ± 3 y.
|Mild to moderate periodontitis in accordance with the AAP criteria.||HbA1c ≥ 7%.||Both groups: OHI, placement of emergency restorations and extraction of unsalvageable teeth. Treatment group: SRP.||Age, gender, smoking, other systemic diseases.||After 3 mo, HbA1c showed an improvement in the treatment group. Control: 8.72 ± 2.22% vs. 8.97 ± 1.82%. Treatment group: 8.15 ± 1.18 vs. 7.41 ± 1.18%, P < 0.001.||Yes|
|Chen et al97, China||134 with T2DM and PD; 45 treatment 1; 45 treatment 2; 44 treatment control;
treatment 1, 59.86 ± 9.48 y, treatment 2, 57.91 ± 11.35 y and treatment control, 63.2 ± 8.51 y.
|Mean CAL ≥ 1 mm (including slight, moderate, and severe periodontitis), with ≥ 16 teeth. In accordance with the AAP criteria.||T2DM for more than 1 year.||Control: no treatment measure or formal oral hygiene instructions. Group 1: SRP at the baseline and additional subgingival debridement at the 3-mo follow-up. Group 2: SRP at the baseline only.||Age, gender, smoking status, alcohol, physical exercise, BMI.||No differences were observed in HbA1c in month 1.5 and 3. After 6 mo, only group 2 had a significant reduction in the HbA1c. Control: 7.25 ± 1.49 to 7.38 ± 1.57%; Group 1: 7.31 ± 1.23 to 7.09 ± 1.34%; Group 2: 7.29 ± 1.55 to 6.87 ± 1.12%, P < 0.05.||Yes|
|Koromantzos et al98, Greece||60 patients with T2DM and PD; no controls;
Mean age: 59.5 ± 8.9 y.
|≥ 16 teeth with at least 8 sites with PD ≥ 6 mm and 4 sites with CAL ≥ 5 mm, distributed in at least 2 different quadrants.||HbA1c 7% > 10%.||Teeth with hopeless teeth were extracted at SRP visit. Control: periodontal prophylaxis at baseline; Treatment group: SRP||Age, gender, smoking, BMI.||After 6 mo, HbA1cshowed an improvement in the treatment group. Treatment vs. control group: −0.72 ± 0.93%, P < 0.001.||Yes|
|Sun et al88, China||157 patients with T2DM and PD;
82 treatment group, 72 treatment control;
Mean age: treatment group, 55.13 ± 11.16 y, and treatment control,
54.23 ± 10.85 y.
|≥ 20 teeth with at least 60% of the teeth with PD > 5 mm, more than 30% of the teeth with CAL > 4 mm, or over 60% of the teeth with PD > 4 mm and CAL > 3 mm.||T2DM for more than 1 year; HbA1c 7.5% > 9.5%.||All patients had OHI, SRP, periodontal flap surgery when indicated, extraction of hopeless teeth, and restore of balanced occlusion. Antibiotics were prescribed||Age, gender, BMI, smoking, systemic diseases.||After 3 mo, HbA1c showed an improvement in the treatment group. Control: −0.14 ± 0.12; Treatment group: −0.50 ± 0.18; P < 0.01.||Yes|
|Katagiri et al99, Japan||49 patients with T2DM and PD;
32 treatment group, 17 treatment control;
Mean age: treatment group, 59 ± 9.9 y, and treatment control, 59 ± 4.8 y.
|≥ 11 teeth, at least 2 pocket sites with PD ≥ 4 mm.||HbA1c 6.5% > 10.0%.||Control: OHI. Treatment group: SRP and 10 mg of minocycline ointment topical in every periodontal pocket at the end of each visit. The intensive periodontal treatment was completed over the course of four visits within 2 mo.||Age, gender, BMI, CRP.||After 1 mo, HbA1c showed an improvement in the treatment group. After 3 and 6 mo, HbA1c were not statistically significant. Multiple regression analysis revealed that BMI and change in CRP correlated significantly with the reduction of HbA1c at 6 mo after the periodontal treatment.||Yes|
|Llambes et al100, Spain||60 patients with T1DM and PD; 30 group 1, 30 group 2; Mean age 35.3 ± 9 y.||≥ 14 teeth; at least 5 teeth with PD ≥ 5 mm and CAL ≥ 3 mm.||T1DM for more than 1 y; 22 patients with HbA1c < 7%, 15 patients with HbA1c 7% > 8%, and 23 patients with HbA1c > 8%. They were equal- ly distribu- ted into 2 groups.||Group 1: SRP plus Chlorhexidine for 12 weeks plus doxycycline 100 mg/day for 15 days; Group 2: same treatment as group 1 with the exception of the doxycycline.||Age, gender, smoking, systemic diseases.||After 3 mo, no difference in HbA1c was observed. Group 1: 7.64 ± 1.81% to 7.71 ± 1.74%; Group 2: 7.51 ± 1.36% to 7.45 ± 1.29%.||No|
|O’Connell et al101, Brazil||30 patients with T2DM and PD; 15 group 1, 15 group 2; Mean age: 52.9 y.||≥ 1 site with PD ≥ 5 mm, and two teeth with CAL ≥ 6 mm.||T2DM for more than 5 y; HbA1c > 8%.||Group 1: SRP with doxycycline 100 mg/ day, for 2 wk after an initial dose of 200 mg; Group 2: SRP with placebo.||Age, gender, smoking, systemic diseases.||After 3 mo, HbA1c showed an improvement in the group 1. Group 1: 11.8 ± 1.6% vs. 10.3 ± 2.3%; P < 0.01. Group 2: 10.7 ± 2.0% vs. 9.8 ± 2.0%.||Yes|
|Singh et al102, India||45 patients with T2DM and PD; 15 group 1, 15 group 2 and 15 group 3;
Mean age not stated.
|≥ 16 teeth, ≥ 30% of the teeth examined having PD ≥ 4 mm. Teeth with poor prognosis were extracted.||Not stated.||Group A: SRP. Group B: SRP + systemic doxycycline (100 mg daily for 14 d). Group C: no treatment.||Age, gender, systemic diseases.||After 3 mo: Fasting plasma glucose levels: non-significant. 2-h postprandial glucose: A: −16.6, B: −21.8, and C: 1.7 mg/dl; P < 0.05. HBA1c: A: 0.6, B: −0.7, and C: 0.06; P < 0.05.||Yes|
|Jones et al103, USA||165 patients with T2DM and PD; Mean age: 59.1 ± 11 y.||Community Periodontal Index of Treatment Need (CPITN) scores of ≥ 3 in at least two sextants.||HbA1c ≥ 8.5%.||Group 1: 4 mo SRP plus doxycycline (100 mg daily for 14 d) and CHX rinses twice daily for 4 mo, then usual care. Group 2: Early treatment, continued for 12 mo. Participants were seen every 4 mo for SRP. No additional antimicrobials used. Group 3: Usual care, then 4 mo of treatment, followed by usual care. Group 4: Usual care, then 12 mo of treatment as in group 2.||Age, gender, smoking, BMI (self-report), stress, systemic diseases, alcohol.||After 4 mo, no differences in HbA1c change for either the unadjusted or adjusted analyses were observed (0.63% vs. 0.61%, unadjusted, 0.51% versus 0.65%, adjusted for baseline HbA1c, age ≥ 55 y, and diabetes duration).||No|
|Kiran et al104, Turkey||44 patients with T2DM and PD; 22 treatment, 22 treatment control; Mean age 54.4 ± 11.7 y.||The parameters were only presented in the results section. PD: 2.29 ± 0.49 and CAL: 3.19 ± 1.13 mm.||HbA1c: 6% > 8%.||Control group: no treatment; Treatment group: OHI and SRP.||Age, gender, smoking.||After 3 mo, HbA1c showed an improvement in the treatment group. Control: 7.00 ± 0.72% to 7.31 ± 2.08%; treatment group: 7.31 ± 0.74% to. 6.51 ± 0.8%; P < 0.05.||Yes|
|Rodrigues et al105, Brazil||30 patients with T2DM and PD; 15 treatment group, 15 control group; Mean age: 50.29 ± 3 y.||≥ 1 site with probing depth ≥ 5 mm and two teeth with attachment loss ≥ 6 mm||Patients were diagnosed with T2DM. HbA1c was not stated.||Control: OHI and SRP. Treatment group: OHI, SRP plus amoxicillin/clavulanic acid (875 mg twice daily for 2 wk).||Age, gender, smoking.||After 3 mo, HbA1c showed an improvement in the treatment group. Control: 9.5 ± 2.4% to 9.2 ± 1.6%, treatment group: 8.8 ± 1.8% to 7.6 ± 1.4%; P < 0.05.||Yes|
|Al- Mubarak et al106, USA||52 patients;
12 with T1DM and 40 with T2DM; 26 in each treatment group;
Mean age: 51.3 ± 13 y.
|≥ 14 non-crowned teeth with supragingival calculus in ≥ 4 teeth in 2 different quadrants, but no gross oral neglect or advanced periodontitis.||PD ≥ 5mm but 8 mm in ≥ one site in 4 teeth in ≥ 2 quadrants. Teeth should not show profound mobility or furcation involvement.||DM for more than 1 year. HbA1c was not stated. Control: OHI. Treatment group: OHI, SRP plus they were instructed to use powered oral irrigator.||Age, gender, systemic diseases.||After 3 mo, no statistically significant difference in the HbA1c between the two groups. Control: 8.06 ± 0.29 to 7.7 ± 0.36. Treatment group: 8.5 ± 0.31 to 8.3 ± 0.36.||No|
|Stewart et al107, USA||72 patients with T2DM and PD; 36 treatment group, 36 treatment control;
Mean age: treatment group, 62.4 ± 8.4 y, and treatment control, 67.3 ± 10.8 y (significant age difference between the groups (P < 0.05)).
|Not stated.||HbA1c criteria not stated. Results: Control: 8.5 ± 2.1%; Treatment group: 9.2 ± 2.2%.||Control: The dental status was unknown. Treatment group: OHI, SRP and extraction of teeth with excessive alveolar bone loss or periapical infections.||Age, diet, medication, ethnicity.||After 9 mo, HbA1c showed a higher improvement in the treatment group. Control: 6.7% improvement in HbA1c vs. 17.1% improvement in the HbA1c in the treatment group.||Yes|
AAP = American Academy of Periodontology; CAL = clinical attachment level; CPT = control periodontal treatment; CRP = C-reactive protein; DM = diabetes mellitus; HbA1c = glycated haemoglobin; IPT = intensive periodontal therapy; OHI = oral hygiene instructions; PD = probing depth; ROS = reactive oxygen species; SRP = scaling and root planing; T1DM = type-1 diabetes mellitus; T2DM = type-2 diabetes mellitus. Only studies with SRP, ± surgery and ± antibiotics were included, other therapies, such as lasers, were not listed. All listed studies used HbA1c as a primary outcome.
Table 1-5 Clinical studies assessing the epidemiological association between periodontitis and T1DM
|Type of study||Study, country||Subjects||Findings|
|Case-cohort||Firatli109, Turkey||44 subjects with T1DM and 20 healthy controls. Length of the study: 5 y.||CAL was higher in the T1DM subjects. Positive correlation between the duration of diabetes and CAL. Fructosamine was correlated with the Gingival Index in the T1DM group.|
|Case-control||Ajita et al110, India||28 subjects with T1DM and 20 healthy controls.||T1DM had greater Bleeding Index, PPD and CAL. Patients diagnosed for diabetes for shorter duration of time (4–7 y) showed Bleeding Index-disease severity correlation.|
|Kaur et al111, Germany||145 subjects with T1DM paired with 2647 healthy controls, and 182 T2DM paired with 1314 healthy controls.||T1 and T2DM had greater CAL. After age stratification, the effect of T2DM was only statistically significant in the 60–69-year-old subjects. T1DM was positively associated with tooth loss. The association between T2DM and tooth loss was statistically significant only for females.|
|Silvestre et al112, Spain||90 subjects with T1DM and 90 healthy controls.||T1DM had greater Bleeding Index, PPD and CAL. Deficient metabolic control and presence of diabetic complication were associated with higher BoP and PPD.|
|Lalla et al113, USA||350 children with T1DM and 350 healthy (6–18 y old). 7% had T2DM.||DM had increased gingival inflammation and CAL than healthy controls with OR ranging from 1.84 to 3.72.|
|Al-Shammari et al114, Kuwait||29 subjects with T1DM of ≤ 5 y duration and 29 subjects with T1DM of > 5 y duration.||T1DM of > 5 y duration had greater number of missing teeth and CAL. Patients with one or more DM complications had greater number of missing teeth and CAL.|
|Pinson et al115, USA||26 subjects with T1DM and 24 healthy controls.||No differences in CAL, PPD, recession, Gingival Index, Plaque Index, gingival fluid flow, or BoP. Site-specific comparison measurements showed the Gingival Index to be somewhat higher among the T1DM subjects. Examination of interaction effect plots showed the T1DM subjects to have higher average Gingival Index for most teeth and higher or the same Plaque Index levels on all teeth relative to controls.|
|Case-control||Seppälä et al116, Finland||38 dentate subjects with a mean duration of 18 years of T1DM.||After 1 and 2 y from baseline, the poorly controlled T1DM subjects exhibited higher BoP than T1DM subjects. After 2 y from baseline, the poorly controlled T1DM subjects exhibited more sites with loss of approximal alveolar bone than T1DM subjects.|
|Seppälä et al117, Finland||38 dentate subjects with a mean duration of 18 years of T1DM.||At baseline and after 1 and 2 y from baseline the poorly controlled T1DM subjects had more gingivitis and BoP than the controlled T1DM subjects.|
|de Pomme- reau et al118, France||85 subjects with T1DM and 38 healthy controls.||T1DM children had more gingival inflammation than healthy controls.|
|Cross-sectional||Patiño Marín et al119, Mexico||35 subjects with T1DM with HbA1c between 6.5% and 7%; 35 subjects with T1DM with HbA1c > 7%; 35 subjects without T1DM; 35 subjects with T2DM; and 35 subjects without T2DM.||No differences among in frequency of caries, filled teeth, missing teeth, prosthetic restoration, bacterial dental plaque, Calculus Index, PPD and CAL between T1DM and healthy controls. T2DM subjects had more missing teeth, calculus, PPD and CAL.|
|Patiño Marín et al120 Mexico||20 subjects with uncontrolled T1DM, 20 subjects with controlled T1DM, and 40 healthy controls.||The imbalance of glucose of subjects with T1DM was associated with more frequency of periodontal disease.|
BoP = bleeding on probing; CAL = clinical attachment level; HbA1c = glycated haemoglobin; OR = odds ratio; PPD = pocket probing depth; T1DM = type 1 diabetes; T2DM = type-2 diabetes.
● The prevalence of diabetes is 13.1% among subjects with periodontitis and 9.6% among subjects without periodontitis according to a 2018 meta-analysis.
● There is strong evidence for an association between periodontitis and glycaemic status, expressed as HbA1c, fasting blood glucose levels and/or glucose tolerance test, the latter in people without diabetes.
● HbA1c is significantly reduced at 3 to 4 months following periodontal therapy. However, there are insufficient data to demonstrate that this effect is maintained after 6 months.
● Some studies identified that periodontitis increases insulin resistance (HOMA-IR levels) in people with diabetes.
● People with diabetes and periodontitis are more likely to suffer from diabetes-related complications than people with diabetes only.